|Articles|July 25, 2022
Validation of ICON™ Automated Cell Counting and Viability Assay
Author(s)Advanced Instruments
This benchmarking study compares the Advanced Instruments Solentim ICON™ viability assay to the performance of a commercially available cell counter. The results demonstrate lower variation, increased precision, and time savings.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
2
How Biopharma Navigates the 2026 Economic Shift
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5